Ph II CABOGIST in GIST

Ph II CABOGIST in GIST

Gastrointestinal Stromal Tumor

Active, not recruiting

2

Start Date 02/02/2017

Age of Trial (yrs) 8.2

Gleevec-resistant

KIT/PDGFRA inhibitor + MET/VEGF inhibitor

Block KIT + Block related tumor signal paths

Specifically GIST and only GIST

EORTC-1317, 2014-000501-13

European Organisation for Research and Treatment of Cancer - EORTC

Sents +3227741533 ward.sents@eortc.be

Oral

The study is a multi-center, multi-national, open label, single arm Phase II study of single-agent cabozantinib. The objective of the study is to assess the safety and activity of cabozantinib in patients with metastatic GIST who have previously progressed on imatinib and sunitinib and have not been exposed yet to other KIT- or PDGFR-directed tyrosine kinase inhibitors.

Patient will receive cabozantinib until they experience no further benefit from the treatment, becoming intolerant to the drug or wishing to discontinue the treatment. Treatment beyond RECIST 1.1 progression is allowed in patients deriving clinical benefit upon investigator's discretion, provided no other criteria for treatment withdrawal are met.